Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ: MDGL )

312.35 +0.35 (+0.11%)
Streaming Delayed Price Updated: 11:54 AM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH
The company hopes to be the first to the finish line with a treatment for MASH. 
Via Investor's Business Daily
Madrigal Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Analyst Ratings for Madrigal Pharmaceuticals
Via Benzinga
2 Risky Stocks With Massive Potential
Neither is doing well this year. 
Via The Motley Fool
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be in store for all three of these drugmakers. 
Via The Motley Fool
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
This business could be on the cusp of making medical history. 
Via The Motley Fool
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
The company might have a bright future, but is now the right time to buy shares? 
Via The Motley Fool
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
2 Rising Biotechs That Could Become the Next Novo Nordisk
Each of these companies has a big market in its sights. 
Via The Motley Fool
2 Stocks That Could Soar This Year: Are They Buys?
They might perform well in 2024, but how will they do beyond that? 
Via The Motley Fool
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
3 Stocks That Could Be Monster Winners in 2024
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. 
Via Benzinga
These 2 Stocks Could Be About to Soar: Are They Buys?
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
These stocks just might have investors seeing double over the next few years. 
Via The Motley Fool
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nike, Carnival And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today?
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28. 
Via Benzinga
Topics Stocks
Exposures US Equities
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.
It has a good shot at commercializing a drug to treat a common liver disease. 
Via The Motley Fool
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.